Wall Street Analysts See Upside Potential for 5 Stocks with Rising Price Targets

Page 5 of 5

01. Neumora Therapeutics, Inc. (NASDAQ:NMRA)

Upside Potential: 55%

On March 18, JPMorgan Chase & Co. revised upward its price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA), a pharmaceutical company operating within the healthcare industry. This adjustment involved increasing the price target from $20.00 to $22.00, indicating the firm’s positive outlook on the company’s growth prospects and overall value. Neumora Therapeutics, Inc. (NASDAQ:NMRA) operates in the pharmaceutical sector, which plays a crucial role in developing innovative treatments and therapies to address various medical conditions. The company focuses on researching and developing novel drugs to meet unmet medical needs and improve patient outcomes. With the revised price target, JPMorgan Chase & Co. suggests an upside potential of 55% for Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock compared to its current market price of $14.16. This indicates the firm’s confidence in Neumora’s ability to generate substantial returns for investors in the future.

The “overweight” rating assigned by JPMorgan Chase & Co. reflects its belief that Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock is poised to outperform the broader market. This rating takes into account factors such as the company’s pipeline of promising drug candidates, potential for regulatory approvals, and anticipated market demand for its products. By increasing the price target and assigning an “overweight” rating, JPMorgan Chase & Co. signals its bullish stance on Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock and encourages investors to consider it as an attractive investment opportunity. This endorsement underscores the firm’s confidence in Neumora’s growth trajectory and potential to deliver value to shareholders in the long term.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily enewsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out Forget Magnificent Seven: Jim Cramer Likes These ‘Super 7’ European Stocks and 12 Best Artificial Intelligence (AI) Stocks To Buy According to Financial Media

Page 5 of 5